Wang Zhuoran

Sr Scientist II
Novo Nordisk A/S
Beijing, Beijing, China (People's Republic)

Presentation(s):

• OC 21.1 - Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A

  Sunday, June 23, 2024
  14:45 – 15:00 ICT